Description

FURAZOLE -D TAB

Indications

Furazolidone, the active ingredient in FURAZOLE -D TAB, is primarily indicated for the treatment of gastrointestinal infections caused by susceptible organisms. It is effective against various protozoal infections, including giardiasis and amoebiasis. Additionally, it is utilized in the management of bacterial infections, particularly those caused by Gram-negative bacteria. This medication is often prescribed for patients with diarrhea or dysentery due to its antimicrobial properties.

Mechanism of Action

Furazolidone exerts its antimicrobial effects through the inhibition of bacterial enzyme systems. It is a nitrofuran derivative that works by interfering with the bacterial metabolism, particularly by inhibiting the synthesis of nucleic acids and proteins. This action leads to the disruption of the bacterial cell wall and ultimately results in cell death. Furthermore, furazolidone is believed to generate reactive intermediates that damage microbial DNA, contributing to its effectiveness against a broad spectrum of pathogens.

Pharmacological Properties

Furazolidone is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations typically achieved within 1 to 2 hours after oral administration. The drug is metabolized in the liver and excreted primarily via the urine. The half-life of furazolidone ranges from 2 to 4 hours, which necessitates multiple doses throughout the day to maintain therapeutic levels. The drug’s pharmacokinetics can be influenced by factors such as age, liver function, and the presence of other medical conditions.

Contraindications

FURAZOLE -D TAB is contraindicated in patients with a known hypersensitivity to furazolidone or any of its components. It should not be used in individuals with a history of severe liver disease or renal impairment, as these conditions may increase the risk of adverse effects. Additionally, the use of this medication is contraindicated in patients who are concurrently taking monoamine oxidase inhibitors (MAOIs) due to the potential for hypertensive crises.

Side Effects

Common side effects associated with the use of FURAZOLE -D TAB include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. Other potential adverse effects may include headache, dizziness, and allergic reactions such as rash or itching. In rare cases, more severe reactions may occur, including hemolytic anemia and peripheral neuropathy. Patients should be advised to report any unusual or severe side effects to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of FURAZOLE -D TAB varies depending on the specific infection being treated and the age of the patient. For adults, the typical dosage is 100 mg to 200 mg administered orally three to four times daily for a duration of 7 to 10 days. For pediatric patients, the dosage is usually based on body weight, often ranging from 5 mg to 10 mg per kilogram per day, divided into multiple doses. It is essential for patients to follow their healthcare provider’s instructions regarding dosage and duration of therapy to ensure optimal treatment outcomes.

Interactions

FURAZOLE -D TAB may interact with several medications, potentially altering their effects. Notably, the concurrent use of furazolidone with MAOIs can lead to serious hypertensive reactions. Additionally, patients taking medications that affect liver enzymes may experience altered metabolism of furazolidone, leading to increased toxicity or decreased efficacy. It is crucial for patients to inform their healthcare provider of all medications, supplements, and herbal products they are taking to avoid potential interactions.

Precautions

Patients should exercise caution when using FURAZOLE -D TAB, particularly those with pre-existing liver or kidney conditions. Regular monitoring of liver function tests may be necessary during treatment. Additionally, patients should be advised to avoid alcohol consumption during therapy, as this can increase the risk of adverse reactions. Pregnant and breastfeeding women should consult their healthcare provider before using this medication, as safety during pregnancy and lactation has not been fully established.

Clinical Studies

Clinical studies have demonstrated the efficacy of furazolidone in treating various gastrointestinal infections. In one randomized controlled trial, patients with giardiasis treated with furazolidone showed a significant reduction in symptoms and parasite load compared to those receiving placebo. Another study highlighted the effectiveness of furazolidone in managing bacterial diarrhea, with a notable improvement in stool consistency and frequency among treated individuals. These findings support the use of FURAZOLE -D TAB as a valuable therapeutic option in the management of specific infectious diseases.

Conclusion

FURAZOLE -D TAB is an effective antimicrobial agent indicated for the treatment of gastrointestinal infections caused by susceptible organisms. Its mechanism of action involves the inhibition of bacterial metabolism, leading to cell death. While generally well-tolerated, it is essential for patients to be aware of potential side effects and drug interactions. Proper dosing and adherence to medical advice are crucial for achieving optimal therapeutic outcomes. As with any medication, patients should consult their healthcare provider for personalized recommendations and guidance regarding the use of FURAZOLE -D TAB.